Minerals in thalassaemia major patients: An overview

J Trace Elem Med Biol. 2017 May:41:1-9. doi: 10.1016/j.jtemb.2017.01.001. Epub 2017 Jan 16.

Abstract

Thalassaemia major (TM) is a hereditary blood disease characterised by reduced or absent production of beta globin chains. Erythrocyte transfusions are given to raise the haemoglobin level in patients with thalassaemia major. However, transfusions have been related to increased risk of iron overload and tissue damage related to excess iron. Both elevated oxidative stress due to iron overload and increased hemolysis lead to over utilisation of minerals required for antioxidant enzymes activities. Iron chelators have been used to prevent iron overload in thalassaemia major patients, but these chelators have the possibility of removing minerals from the body. Thalassaemia patients are more at risk for mineral deficiency because of increased oxidative stress and iron chelation therapies. Growth and maturational delay, cardiomyopathy, endocrinopathies and osteoporosis are the complications of thalassaemia. Minerals may play a particular role to prevent these complications. In the current review, we provide an overview of minerals including zinc (Zn), copper (Cu), selenium (Se), magnesium (Mg) and calcium (Ca) in thalassaemia major patients. We, also, underline that some complications of thalassaemia can be caused by an increased need for minerals or lack of the minerals.

Keywords: Iron; Mineral; Selenium; Thalassaemia; Trace element; Zinc.

Publication types

  • Review

MeSH terms

  • Humans
  • Minerals / administration & dosage
  • Minerals / therapeutic use*
  • Thalassemia / drug therapy*

Substances

  • Minerals